Screener
UroGen Pharma URGN Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 384,986 | 305,929 |
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 135 | 133 |
| Additional paid-in capital | 865,112 | 854,090 |
| Accumulated deficit | (997,641) | (959,716) |
| Accumulated other comprehensive income | (2) | 19 |
| Total shareholders' deficit | (132,396) | (105,474) |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's common stock?
- UroGen Pharma (URGN) reported common stock of $135K in Q2 2026.
- How has UroGen Pharma's common stock changed year-over-year?
- UroGen Pharma's common stock increased by 7.1% year-over-year, from $126K to $135K.
- What is the long-term trend for UroGen Pharma's common stock?
- Over 5 years (2020 to 2025), UroGen Pharma's common stock has grown at a 17.3% compound annual growth rate (CAGR), from $60K to $133K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about UroGen Pharma's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude